Novaremed AG: Novaremed's Non-opioid Lead Compound, NRD.E1, to be Tested in NIH HEAL Initiative Phase 2 Trial for the Treatment of Chronic Pain

NIH, through the Helping to End Addiction Long-term Initiative, to sponsor the Phase 2b SERENDIPITY-1 study, evaluating NRD.E1 in patients with painful diabetic peripheral neuropathy (PDPN)

Related Keywords

United States ,Mark Altmeyer ,Kostenloser Wertpapierhandel ,Eva Tiecke ,Isaac Kobrin ,Early Phase Pain Investigation Clinical Network ,Metys Pharmaceuticals Ag Switzerland ,End Addiction Initiative ,Novaremed Ltd Israel ,National Institutes Of Health ,Us National Institutes Of Health ,End Addiction Long Term Initiative ,National Institutes ,Executive Chairman ,Chief Scientific Officer ,Fast Track Designation ,Painful Diabetic Peripheral Neuropathy ,Randomised Proof ,Concept Study ,European Journal ,Track Designation ,Metys Pharmaceuticals ,Executive Member ,Novaremed ,Opioid ,Head ,Compound ,Tested ,Meal ,Initiative ,Hase ,Trial ,Treatment ,Hronic ,Rain ,